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October 16, 2012:1577–80larly retrospective studies, are more likely to show favorable results
with larger treatment effects (5). In this regard, it is notable that all 3
studies which reported on mortality as an outcome in this review were
retrospective in design, and 2 of the 3 were single-center studies.
Second, the true safety of AVNA in patients who have heart
failure and AF should be assessed over the longer term (not simply
procedural safety) because it results in irreversible pacemaker
dependency. Short-term follow-up may not capture the long-term
risks of an irreversible procedure. What are the long-term risks,
therefore, of pacemaker dependency? The maximum follow-up in
the studies included in the review by Ganesan et al. (1) was a
median of 34 months, which is less than the lifetime of a
pacemaker/defibrillator generator. With significant risks associated
with generator replacement/revisions (particularly in patients with
biventricular pacemakers/defibrillators) (6), the clinical implications of
rreversible pacemaker dependency cannot be easily dismissed. Fur-
hermore, in patients who are less likely to respond to biventricular
acing (e.g., relatively narrow QRS duration and extensive areas of
nfarction), does the potential benefit of AVNA still outweigh the
otential complications of irreversible pacemaker dependency?
Hence, the current picture of AVNA in heart failure is
ncomplete. The need for randomized studies is clear.
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Ursodeoxycholic Acid in Patients
With Chronic Heart Failure
We read with interest the excellent paper written by von Haehling
et al. (1). The authors assessed, in a double-blind, randomized,placebo-controlled, crossover trial, the effects of ursodeoxycholic
acid (UDCA) on endothelial function and inflammatory markers
in patients with chronic heart failure (HF). They concluded that
UDCA improved peak post-ischemic blood flow in the arm and
that there was a trend for improved peak post-ischemic blood flow
in the leg, while liver function was improved. However, it failed to
show benefits in exercise capacity and levels of inflammatory
markers, such as tumor necrosis factor  and interleukin-6,
compared with placebo.
Previously, it was shown that 6 weeks’ UDCA therapy improved
endothelium-dependent, nitric oxide–independent vasodilatation,
which might maintain arterial flow in patients with HF under
conditions of impaired nitric oxide production (2). The present
study expanded the previous knowledge in patients with HF.
Despite the novelty of the present study, and although it was
published many years after the first study of UDCA, there are still
aspects requiring attention, such as the drug dose and the study
period. Furthermore, the implicated underlying pathways are
rather controversial and slightly inexplicable when considering the
unequal improvements of peripheral blood flow in the arms and
legs.
Similarly, we have highlighted previously the beneficial
effects of pharmaceutical agents, different from UDCA, on
endothelial function/inflammatory process in patients with HF,
and we have shown that short-term treatment with rosuvastatin
regulated the inflammatory process in patients with HF by
significantly reducing plasma levels of myeloperoxidase com-
pared with allopurinol and placebo (3). Importantly, treatment
with rosuvastatin, but not allopurinol, significantly increased
the number of circulating endothelial progenitor cells (EPCs) in
patients with HF, providing further insight into its role in these
individuals. This effect on EPCs was not mediated by changes
in inflammatory and oxidative status (4). Considering the
previously published data, we conclude that although the results
of the study by von Haehling et al. (1)are promising and
challenging, these should be considered with care and skepticism.
Agents such as statins and others already evaluated in several
studies are capable of improving endothelial function and decreas-
ing inflammatory process, and therefore further large-scale ran-
domized studies are required to establish the role of UDCA
therapy in patients with HF.
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Absolute Risk Reduction Due
to Statin Use According to Sex
I would like to thank Dr. Mosca for her insightful editorial (1) on
our publication detailing a meta-analysis of the effects of statin use
in women and men (2) and for highlighting the importance of
reduction in absolute risk, particularly in primary prevention. She
also raised the issues of cost and adverse events in this population.
We performed an additional meta-analysis to examine absolute
risk reduction (ARR).
In women, the ARR of the primary endpoint was statistically
significant in primary prevention trials (0.7% [95% confidence
interval (CI): 0.3 to 1.0]; p  0.0004) and more pronounced
(4-fold) in secondary prevention trials (2.8% [95% CI: 1.5 to 4.2];
p  0.0001). The corresponding number needed to treat over a
4-year period was 148 for primary prevention and 36 for secondary
prevention. In men, the ARR of the primary endpoint was also
statistically significant in primary prevention trials (2.3% [95% CI:
1.1 to 3.4]; p  0.0001) and more pronounced in secondaryprevention trials (3.4% [95% CI: 2.0 to 4.7]; p  0.0001). The
corresponding number needed to treat over a 4-year period was 43
for primary prevention and 29 for secondary prevention.
We do not have sufficient data to perform cost-effectiveness
analyses. However, with the availability of high-potency generic
statins, the cost of medication will continue to decrease. Because
there were only 2 studies reporting sex-specific adverse effects, we
are not able to make firm statements about their adverse-effect
profile specific to women. However, their widespread use in both
men and women suggests that they are typically well tolerated. We
agree with Dr. Mosca on the importance of enrolling more women
in clinical trials and that sex-specific data should be included in the
corresponding publications.
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